Citi analyst Geoff Meacham raised the firm’s price target on Merck (MRK) to $120 from $115 and keeps a Neutral rating on the shares post the Q4 report. The firm says the company’s pipeline and launches are intended to ease the impact from the Keytruda loss of execlusivity at the end of the decade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK: